Shield Therapeutics PLC (LSE:STX) - Share price - Overview

Stock Report

Shield Therapeutics PLC STX

Last Price
GBX112.50

Day Change
0.00|0.00%

As of 15/12/2017
10:38:34 GMT | GBX
Minimum 15 Minutes Delay.

Last Close112.50p
Day Range112.00 - 112.00
Mkt Cap131.00Mil
52-Wk Range108.00 - 173.00
Yield %0.00
ISINGB00BYV81293
Volume175
P/E-7.50
P/S373.75
P/CF-11.10

Share Price

Total Returns 15/12/2017

 Chg (%)  
More ...
Shield Therapeutics PLC-23.73 
FTSE 100 TR GBP1.92
 
Financials
201420152016
More ...
Income Statement
Turnover0.000.000.30
Operating Profit-3.39-6.43-12.46
Net Profit-13.43-24.49-15.02
Reported EPS-12.00-22.00-15.00
Balance Sheet
Current Assets0.562.3323.38
Non Current Assets0.450.5329.00
Total Assets1.002.8652.38
Current Liabilities9.003.583.99
Total Liabilities19.2921.503.99
Total Equity-18.28-18.6448.40
Cash Flow
Operating Cash Flow-3.34-4.18-10.26
Net Change in Cash-1.070.2520.25
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-19.27-16.14--6.97---
2018-21.15-17.69--6.36---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
04/10/2017Exercise of OptionMr. Carl Sterritt100.008,8148,814.00
05/07/2017PurchaseDr. Andrew Heath150.003,3345,001.00
28/06/2017PurchaseJoanne Estell150.0020,00030,000.00
28/06/2017PurchaseMr. Peter Llewellyn-Davies150.0010,00015,000.00

Company Profile

Shield Therapeutics PLC is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.

Sector

Drug Manufacturers - Specialty & Generic

Market Position

835 of 1835 Companies

Index

Outlook

(20/09/2017) no outlook statement

Next Event 31/12/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-6.3813.3516.21
Div Yld (E)0.004.164.22
PEG (E)0.0012.161.67
ROCE-80.38177.0416.28
Op Mrgn-4,362.83-9.451.34
EPS Grwth0.008.6210.82
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Andrew Heath
Chief Executive OfficerMr. Carl Sterritt
Chief Financial OfficerDr. Karl Keegan
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.